Development of the International Consortium for Blood Safety [ICBS] HCV panels
Ver/ Abrir
Resumen
To evaluate the sensitivity and specificity of assays used to screen blood for antibody to hepatitis C virus [HCV] infection, the International Consortium for Blood Safety [ICBS] established fully characterized ICBS panels. ICBS collected and characterized 1007 anti-HCV-positive plasma units from geographically diverse origins by ELISA, RIBA, RT-PCR, and sequence-based genotyping, 539 of which met the definition of a true positive. Of these, 200 confirmed positive plasma units, representing the 6 major HCV genotypes, were selected to assemble the true-positive constituents of the panel. The negative panel comprises 181 plasma units collected from the USA. The panels have proved valuable for determining the performance of anti-HCV assays thus permitting national authorities, especially in resource-limited countries, to make informed decisions on selection of affordable and reliable assaysCitación
Diaz, S., Liu, P., Kuhnert, W.L., Healy, M., Prince, A.M. et al. (2008). Development of the International Consortium for Blood Safety [ICBS] HCV panels. EMHJ - Eastern Mediterranean Health Journal, 14 (2), 427-437, 2008 https://iris.who.int/handle/10665/117455